Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00209
|
|||||
| Drug Name |
Verteporfin
|
|||||
| Synonyms |
Visudyne (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Age-related macular degeneration [ICD11: 9B75.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C41H42N4O8
|
|||||
| Canonical SMILES |
CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
|
|||||
| InChI |
InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t38-,41+/m0/s1
|
|||||
| InChIKey |
YTZALCGQUPRCGW-ZSFNYQMMSA-N
|
|||||
| CAS Number |
CAS 129497-78-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 718.8 | Topological Polar Surface Area | 174 | ||
| Heavy Atom Count | 53 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
4.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
104222390
, 104253378
, 124757496
, 125164300
, 126682291
, 135016992
, 135692277
, 137005637
, 137240344
, 139249759
, 143338983
, 14840039
, 152159626
, 160963806
, 174006241
, 175269887
, 179149780
, 198953297
, 226397753
, 239240257
, 249896056
, 252158761
, 252451139
, 33089058
, 33089402
, 39384497
, 46506236
, 50064319
, 50071237
, 53788496
, 57362100
, 78440468
|
|||||
| ChEBI ID |
CHEBI:60775
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ABCB6 | Transporter Info | ATP-binding cassette sub-family B member 6 | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| References | ||||||
| 1 | Verteporfin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69. | |||||
| 3 | The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.